WO2003000285A1 - Tissue-specific transporter inhibitor - Google Patents
Tissue-specific transporter inhibitor Download PDFInfo
- Publication number
- WO2003000285A1 WO2003000285A1 PCT/JP2002/006104 JP0206104W WO03000285A1 WO 2003000285 A1 WO2003000285 A1 WO 2003000285A1 JP 0206104 W JP0206104 W JP 0206104W WO 03000285 A1 WO03000285 A1 WO 03000285A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tissue
- specific
- inhibitor
- transporter
- specific transporter
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a tissue-specific transporter having a ligand structure recognized by a tissue-specific transporter and a polymer molecular structure that cannot penetrate a membrane tissue, and a tissue-specific transporter function inhibitor
- a therapeutic agent for a tissue dysfunction disease or a therapeutic agent for suppressing the progression of chronic renal failure which comprises, as an active ingredient.
- the low protein diet described above is an effective tool to control the progression of chronic renal failure, and is widely used at present.However, dietary restriction has problems with patients' quality of life (QOL) and compliance Therefore, new therapeutic strategies such as suppressing oral absorption of proteins are required. Recently, as a new strategy for the treatment of hyperlipidemia, a bile acid transporter It has been reported that cholesterol biosynthesis is suppressed by inhibiting cholesterol (J. Pharmacol. Exp. Ther. 293, 315-20, 2000). Similarly, it is expected that the gastrointestinal absorption of proteins can be suppressed by specific inhibitors.
- the present inventors have found that the previously ingested protein degrades into amino acids and oligopeptides in the digestive tract and is absorbed from the small intestine, and that such absorption is present in the small intestinal epithelial cell brush border membrane. It has been reported to be performed by transporters (Pharm. Res. 13, 963-77, 1996). The degraded amino acids are transported by multiple transporters. Oligopeptides are transported by an oligopeptide transporter such as PEPT1 and are specifically absorbed by dipeptide or tripeptide (J Biol. Chem. 270, 6456-63, 1995). It is known that peptides absorb higher digestion products of proteins than small amino acids in the small intestine (Gastroenterology 113, 332-40, 1997).
- PEPT-1 inhibitors are considered to be able to suppress the absorption of protein in the diet, and are useful for patients whose dietary regimen has reduced their QOL.
- the PEPT1 gene was cloned from the small intestine of egrets, humans and rats (J. Biol. Chem. 270, 6456-63, 1995, Nature 368, 563-6, 1994, J. Pharma. Exp. Ther. 275, 1631). -7, 1995, Bioch im. Biophys. Acta, 1305, 34-8, 1996), and transport studies via PEPT1 have developed rapidly.
- the present inventors cloned the PEPT1 gene derived from the rat small intestine for the first time (Biochim. Biophys.
- PEPT 1 is not only a compound with a peptide-like structure such as a 3-lactam antibiotic (Pharm. Res. 13, 963-77, 1996), but also has a peptide bond in the molecule. It has also been reported that it recognizes and transports compounds such as antiviral drug valacyclovir, which it does not have (Biochem. Biophys. Res. Commun. 250, 246-51, 1998, J. Clin. Invest. 101 , 2761-7, 1998, J. Biol. Chem.
- PEPT 1 shows a wide range of substrate recognition properties, but its molecular recognition properties have not yet been elucidated.
- PEPT 1 substrate recognition involves recognition of not only partial structures but also whole molecules. It is believed that they are involved.
- PEPT 2 cloned from kidney (Biochim. Biophys. Acta, 1235, 461-6, 1995, Biochim. Biophys. Acta, 1280, 173-7, 1996, Proc. Natl. Acad. Sci. USA 93, 284) -9, 1996) is located on the brush border membrane of the proximal tubule epithelial cell of the kidney, but has a substrate recognition similar to PEPT 1, and Working on reabsorption. Although the contribution is small, it is known that PEPT1 is also expressed in the kidney (Am. J. Physiol. 276, F658-65, 1999), but expression of PEPT2 in the small intestine has been observed. Not in.
- An object of the present invention is to provide a tissue-specific transport inhibitor that is nonabsorbable in the gastrointestinal tract and that prevents tissue dysfunction due to dietary therapy in patients, and a tissue dysfunction containing such an inhibitor as an active ingredient.
- An object of the present invention is to provide a therapeutic agent for a disease and a therapeutic agent for suppressing progression of chronic renal failure.
- the present inventors believe that in order to solve the above-mentioned problems, it is effective to use a gastrointestinal non-absorbable PEPT1 inhibitor that can avoid recognition of PEPT2.
- a gastrointestinal non-absorbable PEPT1 inhibitor that can avoid recognition of PEPT2.
- the active residue subjected to structural modification was prepared by introducing a dipeptide (Va 1 -Lys) into the supramolecular structure PRX, and as a result of diligent research, the above compound suppressed protein absorption and The present inventors have found that it is possible to suppress the progress of chronic renal failure, which requires restriction of the intake of protein, and have completed the present invention. Disclosure of the invention
- the present invention provides a tissue-specific transport function inhibitor comprising a ligand structure recognized by a tissue-specific transporter and a polymer molecular structure that cannot penetrate a membrane tissue.
- a tissue-specific transport function inhibitor comprising a ligand structure recognized by a tissue-specific transporter and a polymer molecular structure that cannot penetrate a membrane tissue.
- the tissue-specific transporter function inhibitor (Claim 2), or the supramolecular structure according to claim 1
- the polymer molecular structure that cannot penetrate the membrane tissue is a supramolecular structure.
- 3.A tissue-specific transporter according to claim 2 wherein the molecule is a mouth taxane compound in which a linear molecule penetrates a large number of cyclic molecules and both ends of the linear molecule are capped with a bulky substituent.
- tissue-specific transporter function inhibitor (Claim 4) or the linear molecule according to claim 3, wherein the function inhibitor (Claim 3) or the cyclic molecule is cyclodextrin.
- the tissue-specific transporter function inhibitor according to claim 3 or 4 which is ethylene glycol, and the bulky substituent is N-benzyloxycarbodilu-L-phenylalanine.
- the tissue-specific transporter function inhibitor according to any one of claims 3 to 5 (Claim 6), and the polymer molecular structure that cannot penetrate a membrane tissue is an ⁇ -cyclodextrin structure.
- tissue-specific transporter function inhibitor according to claim 1, wherein the ligand recognized by the tissue-specific transporter is an organic anionic substance, an organic cationic substance, or a peptide substance.
- the target is a small intestine-specific transpo 10.
- the present invention relates to the tissue-specific transporter function inhibitor according to claim 0 (claim 11).
- the present invention provides a therapeutic agent for a tissue dysfunction disease comprising the tissue-specific transporter function inhibitor according to any one of claims 1 to 11 as an active ingredient (claim 12).
- Item 10 The therapeutic agent for suppressing chronic renal failure progression, wherein the tissue-specific transporter function inhibitor according to any one of Items 1 to 11 is a protein protein absorption inhibitor, and the inhibitor is an active ingredient. (Claim 13).
- FIG. 1 is a diagram showing a procedure for synthesizing a polymouth taxane.
- FIG. 2 is a diagram showing a procedure for synthesizing a valirulidine derivative recognized by a peptide transporter.
- FIG. 3 is a view showing a procedure for synthesizing a Va 1 _L ys —polymouth taxane conjugate, which is a tissue-specific transporter inhibitor of the present invention.
- FIG. 4 is a graph showing the inhibitory effect of Va1—Lys_poly mouth taxane on the uptake of [ 3 H] Gly—Sar by HeLa—hPEPT1 cells.
- FIG. 5 shows the uptake of [ 3 H] Gly-Sar by HeLa-hPEPTl cells versus the pre-administration of Val_Lys-polymouth taxane or Va1-Lys-monocyclodextrin. It is a figure showing an effect.
- FIG. 6 is a graph showing the results of the time course of plasma concentration of cefadroxil after administration or non-administration of cefaxylene to rats.
- FIG. 7 is a graph showing the results of the time course of plasma concentration of cefadroxil after administration or non-administration of Val_Lys-poly-oral taxane (No. 2) to rats.
- FIG. 8 is a graph showing the results of time-dependent changes in the plasma concentration of cefadroxil after administration or non-administration of Va 1 —Lys—poly-oral taxane (No. 7) to the rat.
- FIG. 9 is a graph showing the results of the time course of the concentration of cefadroxil in plasma when CDX and cephalexin or Val-Lys-poly mouth taxane (No. 2) were administered to the rat. .
- FIG. 10 is a graph showing the results of the time course of plasma concentration of cefadroxil after administration or non-administration of Val_Lys_polymouth taxane (No. 7) to rats.
- FIG. 11 is a graph showing the time course of cefadroxil plasma concentration after administration or non-administration of Val-Lys-poly-oral taxane (No. 7) to rats.
- FIG. 12 is a graph showing the results of the time course of plasma concentration of cefadroxil after administration or non-administration of Val-Lys-poly-oral taxane (No. 7) to rats.
- Fig. 13 shows the time course of the concentration of cefadroxil in plasma when CD X was injected into a rat by intravenous injection and at the same time, oral administration of Val-Lys-poly-oral taxane (No. 7).
- Tissue-specific transporter function inhibitors of the present invention include tissue-specific Any structure may be used as long as it has a ligand structure recognized by a specific transporter and a polymer molecular structure that cannot penetrate the membrane tissue, and inhibits the function of the tissue-specific transporter. Those having a stable structure are preferred.
- Tissues include small intestine, kidney, brain, liver, placenta, ligament, lung, stomach, ovary, testis, spleen, large intestine, skeletal muscle, airway, bone marrow, prostate, heart, uterus, spinal cord, adrenal gland, thyroid, etc.
- Specific examples of transporters specifically expressed in such tissues include, but are not limited to, the transporters shown in Tables 1 to 3. Not something.
- the high molecular weight structures that cannot penetrate the membrane tissue include small intestine, kidney, brain, liver, placenta, kidney, lung, stomach, ovary, testis, spleen, large intestine, skeletal muscle, respiratory tract, bone marrow, prostate, heart, uterus
- Any material having a high molecular structure that cannot be permeated or hardly permeated from biological membrane tissues such as spinal cord, adrenal gland, and thyroid gland may be used.
- Specific examples thereof include a supramolecular structure such as a polymouth taxane compound in which both ends of a linear molecule are capped with a bulky substituent, a derivative containing 1-cyclodextrin, and an inclusion structure.
- cyclic molecule examples include, but are not limited to, cyclodextrin, ⁇ , ⁇ , or molecules such as arcyclodextrin, crown ether, and cyclofructan.
- linear molecule examples include molecules such as polyethylene glycol, polypropylene dalicol, a copolymer of polyethylene drencol and polypropylene dalicol, polyamino acids, and polysaccharides. Polyethylene glycol or the like, which can introduce phenol, is preferred.
- the bulky substituent may be any as long as it prevents elimination of the above cyclic molecule.
- ⁇ _benzyloxycarbonyl-L-phenylalanine, alanine, valine, leucine, Oligos consisting of isoleucine, methionine, proline, phenylalanine, tributofan, aspartic acid, glutamic acid, daricin, serine, threonine, tyrosine, cystine, lysine, arginine, histidine, or a derivative thereof, or an oligo composed of multiple units Peptides and the like can be specifically mentioned, but are not particularly limited.
- tissue-specific transporter examples include substances such as organic anionic substances, organic cationic substances, peptide substances, and substances having an amino group.
- oligopeptide transporter 1 which is a transporter specifically expressed in the small intestine
- oligopeptides such as dipeptides and tripeptides, and modifications of their constituent amino acid residues.
- Specific derivatives i3-lactam antibiotics such as cefadroxil and ceftibutene, ACE inhibitors such as captopril, anticancer drug vestintin, and antiviral antibacterial balashik mouth building. But can be, but not limited to.
- the tissue-specific transporter function inhibitor provided by the present invention is the above-mentioned tissue-specific transporter function inhibitor as a therapeutic agent for tissue dysfunction, and the tissue-specific transporter function inhibitor which suppresses protein absorption as a therapeutic agent for suppressing progression of chronic renal failure.
- These therapeutic agents are preferably contained in a form that can be administered orally, intravenously, intraperitoneally, intranasally, intradermally, subcutaneously, intramuscularly, or the like.
- the effective amount to be administered can be appropriately determined in consideration of the type and composition of the therapeutic agent, the administration method, the age and weight of the patient, and the like, and it is preferable to administer these one to several times a day.
- oral administration it is usually administered in the form of a preparation prepared by mixing with a preparation carrier.
- a preparation carrier that can be used for the preparation, a substance that is commonly used in the field of preparations and that does not react with the tissue-specific transporter function inhibitor of the present invention is used.
- Oral administration can be performed at the same time as a meal or before a meal.
- dosage forms include tablets, capsules, granules, powders, syrups, suspensions, suppositories, ointments, creams, gels, patches, inhalants, injections, etc.
- These preparations can be prepared according to a conventional method.
- they can be dissolved or suspended in water or other suitable medium at the time of use.
- Tablets and granules may be coated by a well-known method.
- the peptide-modified polymer of the present invention It is prepared by dissolving in water, but may be dissolved in physiological saline or a glucose solution as needed, or a buffer or a preservative may be added.
- tissue-specific transporter function inhibitor of the present invention may be used as a food material for improving symptoms of a tissue dysfunction disease or chronic renal failure, such as baked confectionery such as pudding, cookies, pans, cakes, jellies, crackers, and yokan.
- Bread and confectionery such as Japanese sweets, frozen desserts, chewing gum, etc., vegetables such as udon and buckwheat, fish paste products such as kamaboko, ham, fish sausage, yogurt, drink yogurt, juice, milk, soy milk, alcoholic beverages, coffee , Black tea, green tea, green tea, sports drinks and other beverages, miso, soy sauce, dressing, mayonnaise, sweeteners and other seasonings, tofu, konjac, other tsukudani, dumplings, croquettes, salads, etc. It can be added to a side dish and consumed as a functional food.
- vegetables such as udon and buckwheat
- fish paste products such as kamaboko, ham, fish sausage, yogurt, drink yogurt, juice, milk, soy milk, alcoholic beverages, coffee , Black tea, green tea, green tea, sports drinks and other beverages, miso, soy sauce, dressing, mayonnaise, sweeteners and other seasonings, tofu, konjac, other ts
- N-benzyloxycarbonyl-L-phenylalanine Z-L-Phe
- Z represents a benzyloxycarbonyl group
- the carboxyl group of Z-L-Phe was activated.
- N-Hydroxysuccinimide (HOSu) 38.46 g (0.333 mol) and ZL-PhelOOg (0.333 mo1) were converted to dioxane 850 m Dissolved in 1.
- 6.89 g (0.33 mo 1) of N, N'-dicyclohexylcarpoimide (DCC) was added under ice cooling, and the mixture was stirred for about 1 hour.
- water-soluble carbodiimide hydrochloride (WSCHC1) (1.93 g, lOmmol) was added, and the mixture was further stirred at 0 ° C for 2 hours, and then stirred at room temperature for 4 hours, followed by ethyl acetate. Diluted.
- the solution diluted with ethyl acetate was added to a 0.6 M aqueous solution of citric acid (100 ml), water (100 ml), a saturated aqueous solution of sodium hydrogencarbonate (100 ml), water (100 ml), Washing was performed sequentially with 10% saline (100 ml).
- the obtained oil layer was dried over sodium sulfate, concentrated under reduced pressure, and then purified by column chromatography (form-methanol with Sio 2 , 75: 1). The elution peak was confirmed by thin-layer chromatography, and the obtained first fraction was concentrated under reduced pressure and dried under reduced pressure to obtain amorphous white powder Boc-Va1-Lys (Cbz) -Ot- Bu was obtained (3.6 g, yield: 66%).
- the mixture was stirred for 3 days, the palladium carbon was removed by filtration, the solution was concentrated under reduced pressure, and the concentrated solution was subjected to ion-exchange chromatography, using DiaionWA-30 (HC 1 form) as the ion exchanger.
- the solvent was methanol-water (10: 1), and the solution was concentrated under reduced pressure and azeotroped with toluene to obtain a white solid Boc—Val—Lys—Ot_Bu ⁇ HC1. (2.2 g, yield: 51%).
- Example 2 20 mg of polytaxane (-OH: 3 mmo 1) obtained in Example 1 was dissolved in 10 ml of dimethyl sulfoxide (DMS ⁇ ) under a nitrogen atmosphere. After complete dissolution, N, N-dicarbodilimidazole (CDI) was injected with lOOOOmg (6.2 mmO1) and stirring was continued. After 3 hours, unreacted CDI was removed from the reprecipitation in the ether to obtain CDI-activated polymouth taxane (CDI-PRX) 374 mg. The activation rate of the above CDI-PRX was 30%, assuming that 100% was introduced into all the hydroxyl groups.
- CDI-PRX CDI-activated polymouth taxane
- Va1-Lys-polymouth taxane conjugate 113 mg.
- VK-P RX Idani 1
- VK — Hiichi CD two kinds of V a 1 — Lys — Hiichi CD
- VK—P RX and two kinds of VK——CD obtained in Example 3 were each dissolved in 6 N HC 1 in a small amount (1-2 mg), and N 2 was replaced. Next, it was thermally decomposed at 110 ° C. for about 22 hours. After the HC 1 was completely removed, the sample was diluted with 0.02 N HC 1 (2 to 4 m 1) to obtain a sample. The prepared sample was quantified using an amino acid analyzer (Hitachi amino acid analysis form; L-850A). One molecule of VK—P RX or VK—K _CD is obtained from the composition of PK residue and V a1 residue at both ends of VK—PRX or VK—a; —CD obtained by the amino acid analysis method.
- amino acid analyzer Haitachi amino acid analysis form
- Va 1 -Lys per unit (Va1-Lys / VK-PRX or Va1-Lys / VK-HiCD) was calculated using the following two formulas (Table 6 and Table 6). Table 7) ⁇ These two equations were derived as follows. AME t ZP RX in Table 6 and AME t Za—CD in Table 7 indicate the number of aminoethanol (AME t) molecules introduced into VX—PRX or VK—a—CD by proton nuclear magnetic It was calculated from the ratio of the integral value of the methylene peak derived from aminoethanol and the methine peak at the 1st position of anoma in Hi-CD observed on the resonance (H-NMR) spectrum.
- V a 1 — Lys — AME t — RX has two molecules of P he residues per molecule
- the number of moles of the V a 1 — Lys — polyporous taxane conjugate present in the sample to be measured (n RX) is the number of moles of P he residue in the sample n P h.
- equation (1) is obtained. Let nP he be the equation (1).
- n RX 3 ⁇ 4 ⁇ (1)
- the number of introduced V a 1 -L ys per molecule (N V al —L ys ) per molecule of V al —L ys —poly mouth taxane conjugate is V a 1
- the number of moles of the residue is n Va
- the number of moles of Va 1 -L ys —polymouth taxane conjugate is n RX
- 88, 274-80, 2000 were mixed with a multi-dish ( cells were seeded at 1 0 6 cells Z Ueru in Nunc Co.) and cultured for 4 days in 5% C_ ⁇ 2 under I Nkyube one coater at 3 7 ° C (Hirasawa Co.).
- the culture solution used was DMEM (Dulbecco's modified Eagle's medium; Gibco Laboratories) containing 10% FCS (Gibco Laboratories), 2 mM L-glutamine, and 1 mg Zm1G418. . After the culture, the culture solution is aspirated, and each cell is incubated at 37 ° C with Hanks' balanced salt solution (HBSS; 0.9
- HBSS Hanks' balanced salt solution
- the concentration of the inhibitor VK-P RX (No .:! ⁇ 6) was adjusted to a maximum dissolution concentration of 500 or less, and the uptake reaction was performed using a solution filtered with a filter.
- the reaction solution was dispensed from each dish into 10 t1 mini vials, and 4 ml of liquid scintillation cocktail (Clear-sol I, manufactured by Nacalai Tesque) was added, and the liquid scintillation counter was added. (LSC-5100, manufactured by Aloka Co. Ltd.) was used to measure the radioactivity in the reaction solution.
- the reaction solution in each dish was removed by suction, and the reaction was stopped by washing the cells three times with ice-cold HBSS (HE PES: pH 7.4) lm1 three times. Then, add 5N NaOH to each dish to solubilize the cells (2 hours or more), add 5NHC1 to 2501 and neutralize, and then transfer the whole volume to mini vials. 4 ml of a liquid scintillation cocktail (Clear-sol I, manufactured by Nacalai Tesque) was added, and the radioactivity incorporated into the cells was measured.
- HE PES pH 7.4
- VK-Qf-CD No.1
- VK-a-CD No.2 3 77.09 ⁇ 5.67 or -CD 3 125.87 ⁇ 23 ⁇ 4
- VK-PRX (No.2) ⁇ 0.5 76.68 ⁇ 4.62
- VK-PRX (No.3) ⁇ 0.5 131.12 ⁇ 3.75
- VK-PRX (No.4) ⁇ 0.5 6732 ⁇ 8.57
- VK-PRX (No.5) ⁇ 0.5 94.04 ⁇ 4.21
- VK-PRX (No.6) ⁇ 0.5 7720 ⁇ 3.12
- VK-PRX (No.7) 1 52.93 ⁇ 3.69
- VK-PRX (No.7) 0.5 76.08 ⁇ 5.82
- VK-PRX (No.7) 0,3 83.95 ⁇ 10.78
- VK-PRX (No.7) 0.1 104.43 ⁇ 8.70 Cephadole xyl 10 27.69 ⁇ 1.44 Cephalexin 10 70.12 ⁇ 1.45
- VK—PRX No. 7
- VK—Q! —CD No. 2
- [3 H] G ly- influence h PEPT 1 stabilization expression to S ar uptake H e L a cell (H e L a- h PEPT l ) of) when previously preincubated cells did.
- VK- P RX N o 7 .
- V K-alpha - by the presence or absence of pre-incubation of CD N o 2.
- [3 H] G 1 y - see a change in the S ar uptake was done.
- VK—P RX No. 7
- VK—a; —CD No. 2
- VK—PRX No. 7
- Va1—Lys was bound. No inhibitory effect of ⁇ -CD was observed.
- ⁇ H Anesthetized by intraperitoneal administration of 5 Omg / kg Nembutal (manufactured by Dynapot) to 7- to 8-week-old SD (Sprague-Dawley) rats (male; manufactured by Japan SLC). After fixation, apply a force [silicon tube inner diameter X outer diameter (0.5 X 1)] to the jugular vein and femoral vein (only for instantaneous intravenous injection), and then pass the tip under the skin. After penetrating from the back, the incision was joined. Thereafter, the animals were fasted overnight (about 18 hours), and each drug was orally administered by an oral probe, or femoral vein.
- TSKgel ODS-80TS manufactured by Toyo Soda Co., Ltd.
- ultraviolet / visible light detector for the pump, ultraviolet / visible light detector, intelligent autosampler, and column oven, use 880-PU, 875-UV, AS-1555-10, and Co-1565 ( All were manufactured by JASCO Corporation, and the integrator was Chromatopac C-R3A (manufactured by Shimadzu Corporation).
- the mobile phase contained 7% acetonitrile (containing 0.1 M acetate buffer (pH 3.0) and 0.01 M sodium 1-pentanesulfonate). With a flow velocity of 0.9m Separation and elution were performed at 1 / min, and detection was performed at a wavelength of 240 nm.
- Vd (ka-ke),) where C is the concentration of CDX in plasma, F is the absorption rate, D is the dose, ka is the absorption rate constant, ke is the elimination rate constant, Vd represents the distribution volume, and t represents the time at which blood was collected after drug administration.
- hi represents the slope of the distribution phase
- / 3 represents the slope of the disappearance phase
- AUC 0 _ ⁇ AUC 0 _ 6 + C 6 / ke (6)
- AU C represents the area under the one-hour curve of plasma drug concentration
- C 6 represents the plasma concentration six hours after drug administration.
- CL represents systemic clearance
- Dose represents the drug dose
- Vd CLZke (8)
- CEX was orally administered to rats 30 minutes before administration of CDX.
- Each parameter of the pharmacokinetics in each of the above rats was calculated using Equations (4), (6), (7) and (8) based on changes in the blood concentration of CDX. evaluated. The results are shown in FIG.
- the values shown in the figures and tables represent the average values S.E.M. obtained from three or four individual experiments.
- AU C was determined. Saturation was observed in _ ⁇ and Cma.
- the absorption rate when CDX was administered at 2.5 mg / kg was sufficient at 86%.
- CDX was shown to be a suitable compound to evaluate PEPT1-mediated absorption activity, including that it is stable in vivo. Further, when administered to CEX (4 5 mg / kg) of CDX before after administration (2. 5 mg / kg), CDX alone when compared to the plasma concentration - area under the curve (AU C.- ⁇ ) Is reduced by about 30%, the absorption rate constant (ka) is from 2.42 to 1.53 hr— 1 , and the maximum plasma concentration (Cmax) is from 0.8 to 0.5 ⁇ g Zm It decreased significantly to 1. From the above results, the report on humans was reproduced in rats.
- VK-P RK (No. 2) shows the results when VK-P RK (No. 2) was used, and Fig. 8 and Table 11 show the results when VK-P RK (No. 7) was used. Show. The values shown in the figure represent the average value S.EM obtained from 2 to 4 individual experiments, and the values shown in the table represent the average values S.EM obtained from 3 individual experiments. .
- VK—P RK (No. 2) or VK—P RK (No. 7) were co-administered with CDX, but both had AUC compared to CDX alone. -No significant difference was observed in ⁇ ⁇ Also, no significant difference was observed for other parameters overnight. These are already digested at the above dose of CDX (5 mg / kg). It is probable that the effect of VK—P RX (N o 2) was difficult to detect because of saturation in the tube absorption.
- VK-P RX 1 OmgZkg of VK-P RX (No. 2) was administered simultaneously with CDX As in the case (Fig. 7 and Table 10), 5.7 mg / kg of VK-P RX (No. 2) was co-administered with C DX compared to CD X alone when compared with AU C . -No significant difference was found in ⁇ . Similarly, no significant difference was observed for other parameters.
- VK-PRX is a high molecular compound, it is considered that it will not undergo gastrointestinal absorption.
- orally administered CEX promotes excretion of CDX
- VK-PRX is the AUC of CDX.
- CDX has non-linearity in resorption from the kidney (Drug Metab. Dispos. 21, 215-7, 1993, Drug Metab. Dispos. 22, 447-50, 1994).
- an oligopeptide protein transporter is involved in the reabsorption.
- tissue-specific transporter inhibitor of the present invention is not absorbed or hardly absorbed from the small intestine, so that nutrients are absorbed from the small intestine. By specifically lowering the quality of life, it is possible to prevent a decrease in QOL due to diet therapy in patients with tissue dysfunction disease or renal failure. Further, such a tissue-specific transport inhibitor is useful for preventive medicine that does not cause a tissue disease such as a renal disease, and for preservation treatment that does not lead to renal dialysis.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Polyethers (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002313242A AU2002313242B2 (en) | 2001-06-21 | 2002-06-19 | Tissue-specific transporter inhibitor |
CA002451433A CA2451433C (en) | 2001-06-21 | 2002-06-19 | Oligopeptide transporter 1 inhibitor |
EP02738767A EP1405644A4 (en) | 2001-06-21 | 2002-06-19 | TISSUE-SPECIFIC TRANSPORT HEMMER |
US10/742,335 US7420029B2 (en) | 2001-06-21 | 2003-12-19 | Tissue-specific transporter inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001188843A JP3942846B2 (ja) | 2001-06-21 | 2001-06-21 | 組織特異的トランスポーター阻害剤 |
JP2001-188843 | 2001-06-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/742,335 Continuation-In-Part US7420029B2 (en) | 2001-06-21 | 2003-12-19 | Tissue-specific transporter inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003000285A1 true WO2003000285A1 (en) | 2003-01-03 |
Family
ID=19027864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/006104 WO2003000285A1 (en) | 2001-06-21 | 2002-06-19 | Tissue-specific transporter inhibitor |
Country Status (6)
Country | Link |
---|---|
US (1) | US7420029B2 (ja) |
EP (1) | EP1405644A4 (ja) |
JP (1) | JP3942846B2 (ja) |
AU (1) | AU2002313242B2 (ja) |
CA (1) | CA2451433C (ja) |
WO (1) | WO2003000285A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004062691A1 (ja) * | 2003-01-14 | 2004-07-29 | Otsuka Pharmaceutical Co., Ltd. | プロトン駆動型トランスポーター介在型消化管吸収改善剤及びその製法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7420079B2 (en) * | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998007449A2 (de) * | 1996-08-19 | 1998-02-26 | Aventis Research & Technologies Gmbh & Co Kg | Polymere gallensäure-resorptionsinhibitoren mit gleichzeitiger gallensäure-adsorberwirkung |
-
2001
- 2001-06-21 JP JP2001188843A patent/JP3942846B2/ja not_active Expired - Fee Related
-
2002
- 2002-06-19 WO PCT/JP2002/006104 patent/WO2003000285A1/ja active IP Right Grant
- 2002-06-19 AU AU2002313242A patent/AU2002313242B2/en not_active Ceased
- 2002-06-19 EP EP02738767A patent/EP1405644A4/en not_active Withdrawn
- 2002-06-19 CA CA002451433A patent/CA2451433C/en not_active Expired - Fee Related
-
2003
- 2003-12-19 US US10/742,335 patent/US7420029B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998007449A2 (de) * | 1996-08-19 | 1998-02-26 | Aventis Research & Technologies Gmbh & Co Kg | Polymere gallensäure-resorptionsinhibitoren mit gleichzeitiger gallensäure-adsorberwirkung |
Non-Patent Citations (2)
Title |
---|
NAJWA N. IZZAT ET AL: "New molecular targets for cholesterol-lowering therapy", J. PHARMACOL. EXP. THER., vol. 293, 2000, pages 315 - 320, XP002957302 * |
See also references of EP1405644A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004062691A1 (ja) * | 2003-01-14 | 2004-07-29 | Otsuka Pharmaceutical Co., Ltd. | プロトン駆動型トランスポーター介在型消化管吸収改善剤及びその製法 |
JPWO2004062691A1 (ja) * | 2003-01-14 | 2006-05-18 | 彰 辻 | プロトン駆動型トランスポーター介在型消化管吸収改善剤及びその製法 |
JP5175032B2 (ja) * | 2003-01-14 | 2013-04-03 | 彰 辻 | プロトン駆動型トランスポーター介在型消化管吸収改善剤及びその製法 |
US8871818B2 (en) | 2003-01-14 | 2014-10-28 | Otsuka Pharmaceutical Co., Ltd. | Gastrointestinal absorption enhancer mediated by proton-coupled transporter and its preparing method |
Also Published As
Publication number | Publication date |
---|---|
US7420029B2 (en) | 2008-09-02 |
EP1405644A1 (en) | 2004-04-07 |
EP1405644A4 (en) | 2005-04-06 |
US20040191211A1 (en) | 2004-09-30 |
AU2002313242B2 (en) | 2005-06-16 |
JP2003002843A (ja) | 2003-01-08 |
JP3942846B2 (ja) | 2007-07-11 |
CA2451433A1 (en) | 2003-01-03 |
CA2451433C (en) | 2007-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4369986B2 (ja) | アンジオテンシン変換酵素阻害ペプチド | |
JP3494624B2 (ja) | 新規な環状テトラペプチド誘導体とその医薬用途 | |
US6811996B1 (en) | DDS compounds and method for assaying the same | |
TWI583396B (zh) | 腎上腺髓素之聚乙二醇基底前藥及其用途 | |
WO1997046260A1 (en) | Drug complexes | |
CA2621847A1 (en) | Prodrugs of t3 and t4 with enhanced bioavailability | |
EA020613B1 (ru) | Цитотоксические конъюгаты с соединением, связывающим рецептор нейропептида y | |
WO2002000734A1 (fr) | Compose dds et son procede de preparation | |
JP5778692B2 (ja) | 疾病抑制剤 | |
JP3942846B2 (ja) | 組織特異的トランスポーター阻害剤 | |
JPWO2008105441A1 (ja) | リン吸収抑制活性を有するポリアミノ酸化合物及びリン吸収抑制剤 | |
JP2004331630A (ja) | Peg結合ペプチド | |
JP2008297208A (ja) | アンジオテンシンi変換酵素阻害剤 | |
US8772248B2 (en) | Drug delivery system | |
JPH0262559B2 (ja) | ||
JPH0764741B2 (ja) | 栄養組成物 | |
JP2018012694A (ja) | ラパマイシン類結合ブロック共重合体 | |
JPH1121295A (ja) | ハイドロキシプロリン誘導体 | |
WO2002006227A1 (fr) | Inhibiteurs de la metalloprotease matricielle | |
JP2023551480A (ja) | ビオチン部分、脂肪酸部分またはその組合せを連結されて有する生物学的活性材料結合体の経口製剤 | |
CN117659002A (zh) | 一种基于n端法则诱导bcr-abl降解的protac化合物及其应用 | |
CN114989259A (zh) | 一种小分子肽Ped4及应用 | |
CN117534727A (zh) | 一种食源性降压肽的制备方法和应用 | |
CN112294972A (zh) | Psma激活式抗肿瘤前药cpt-y及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10742335 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002738767 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2451433 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002313242 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2002738767 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002313242 Country of ref document: AU |